Ignite Creation Date:
2025-12-26 @ 2:41 PM
Ignite Modification Date:
2025-12-26 @ 2:41 PM
Study NCT ID:
NCT04541706
Status:
COMPLETED
Last Update Posted:
2024-12-20
First Post:
2020-08-21
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Sponsor:
Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-27
Start Date Type:
ACTUAL
Primary Completion Date:
2022-07-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-07-20
Completion Date Type:
ACTUAL
First Submit Date:
2020-08-21
First Submit QC Date:
None
Study First Post Date:
2020-09-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-07-03
Results First Submit QC Date:
None
Results First Post Date:
2024-12-20
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-07
Last Update Post Date:
2024-12-20
Last Update Post Date Type:
ACTUAL